Xcell

About Xcell

Xcell Therapeutics is a South Korean biotechnology company specializing in the research, development, and production of cell culture media for the regenerative medicine and cell and gene therapy (CGT) industries. Founded in September 2015 by CEO Yi-il Lee, the company's mission is to contribute to the future of humanity through the advancement of science and technology. Yi-il Lee was recognized for his contributions to the advanced regenerative medicine industry with an award from the Minister of Health and Welfare in August 2024.

The company's core product is CellCor™, the world's first GMP-grade, serum-free, chemically defined media (CD media) for mesenchymal stem cells (MSCs). Developed after more than a decade of research, CellCor™ is composed of over 200 known compounds and contains no animal or plant-derived components, which enhances safety, quality, and consistency for cell therapy production. This addresses the industry's shift away from traditional media that uses bovine serum, an approach that also aligns with the company's commitment to eco-friendly practices by reducing reliance on cattle. Xcell Therapeutics operates a GMP-certified manufacturing facility in Yongin with an annual production capacity of 100,000 liters, which received FDA 510(k) listing in 2020.

Beyond its primary focus, Xcell Therapeutics has expanded its product pipeline. The company developed 'Celluty', a cosmetic ingredient based on stem cell culture media technology designed to enhance skin regeneration, whitening, moisturizing, and anti-aging functions. It also launched the "Exodus T-2800", an automated system for the high-yield isolation and purification of high-purity exosomes, which are crucial for intercellular communication and have applications in tissue regeneration. The firm serves a global market, with distributors in Europe and the US, and has established exclusive distribution agreements in France, the UK, and Singapore.